HTP Journal Club
The Hematology Training Program Journal Club is held every Tuesday at 3:00 pm – 4:00 pm in the Evans Biomedical Research Center (EBRC) X Building, Fourth floor conference Room 428.
Representative recent Journal Club articles are:
1) “Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation” by Harvey Lodish and colleagues (PNAS 102: 18962-18967, 2005).
2) “Activating mutations in Notch1 in human acute T cell lymphoblastic leukemia” by Jon Aster and colleagues (Science 306:269-271, 2004).
3) “Bcl10 and MALT1, Independent Targets of Chromosomal Translocation in MALT Lymphoma, Cooperate in a Novel NF-B Signaling Pathway” by Gabriel Nunez and colleagues (JBC 276:19012-19019, 2001).
4) “Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412” by Nicki Panoskaltsis and colleagues (NEJM 355: 1018-1028, 2006) and “Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis” by Ralf Gold and colleagues (JEM 202: 445-455, 2005).
5) “A phase II study of bortezomib in relapsed, refractory multiple myeloma” by Kenneth Anderson and colleagues (NEJM 348: 2609-2617, 2003) and “Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.” by Kenneth Anderson and colleagues (Cancer Research 66: 184-191, 2006).
6) “Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412” by Richard Stone and colleagues (Blood, 105:54-60, 2006) and “The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice” by Christian Buske et al (J.Clin.Invest. 115: 2159-2168, 2005).
7) “Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice” by Tasuku Honjo and colleagues (PNAS 104: 1616-1620, 2007) and “Activation-induced deaminase: light and dark sides” by Almudena Ramiro et al (Trends in Molecular Med, 12: 432-439, 2006).
8) “Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma.” By Craig Thompson and colleagues (J Clin Invest 117(2), 326-336, 2007).
9) “Despite inhibition of nuclear localization of NF-B p65, c-Rel, and RelB, 17-b estradiol up-regulates NF-kB signaling in mouse splenocytes: The potential role of Bcl-3.” by Ansar Ahmed and colleagues (J. Immunol. 179:1776-1783, 2007).
10) “Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3” by Ronald J. Falk and colleagues (Nature Medicine 10:72-79. 2004) and “Role of complementary proteins in autoimmunity: an old idea re-emerges with new twists.” by Kathleen McGuire and David S. Holmes (Trends in Immunology 26: 367-372, 2005).
11) “Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability” by Gladwin and colleagues (Blood 109:3088-3098, 2007). “Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes” by Gregory J. Kato, Mark T. Gladwin and Martin H. Steinberg (Blood Reviews 21:37-47, 2007).
12) “Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets” by Weyrich and colleagues (Cell, Vol. 122, 379-391, August 12, 2005) and “The biogenesis of platelets from megakaryocyte proplatelets.” by Italiano and colleagues (J Clin Invest, 115: 3348-3354, 2005).
13) “Transfusion-induced autoantibodies and differential immunogenicity of blood group antigens: a novel hypothesis” by Hillyer and colleagues (Transfusion 47:2189-2196, 2007).
14) “Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor” by Howard Weiner and colleagues (Nature 453: 65-71, 2008).
15) “Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome” by Jing Zhao et al (Science 322: 750-756, 2008).
16) “Vasoactivity of S-nitrosohemoglobin: role of oxygen, heme, and NO oxidation states” by Jack H. Crawford, C. Roger White, and Rakesh P. Patel (Blood. 2003;101:4408-4415).
17) “Oncogenic CARD11 mutations in diffuse large B cell lymphoma” by Louis M. Staudt and colleagues (Science 319, 1676, 2008) and “The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes” by D.J. Rawlings, K. Sommer and M. Moreno-Garcia (Nature Reviews Immunology 6: 799-812).
18) “High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow” by David Price and colleagues (Blood 2009;113:2238-2244).
19) “Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection” by Luc English et al (Nature Immunology published online March, 2009) and “Autophagy and Its Role in MHC-Mediated Antigen Presentation” (J. Immunol. 182:3335-3341, 2009) and “Autophagy: Principles and significance in health and disease” (Biochimica and Biophysica Acta 1792: 3-13, 2009).
20) “BCL6-mediated Attenuation of DNA Damage Sensing Triggers Growth Arrest and Senescence through a p53-dependent Pathway in a Cell Context-dependent Manner” by Ari Melnick and colleagues (J. Biol. Chem. 2008, 283, 22565-22572) and “The Bcl6 proto-oncogene: a leading role during germinal center development and lymphomagenesis” by Herve Tilly and colleagues (Pathologie Biologie 2007 55:73-83).
21) “Rb intrinsically promotes erythropoiesis by coupling cell cycle exit with mitochondrial biogenesis” by Carl Walkley and colleagues (Genes Dev. 2008, 22: 5463-475) and “The axis of mTOR-mitochondria-ROS and stemness of the hematopoietic stem cells” by Pan Zheng and colleagues (Cell Cycle 2009, 8: 1158-1160).
22) “Basophils Play a Pivotal Role in Immunoglobulin-G-Mediated but Not Immunoglobulin-E-Mediated Systemic Anaphylaxis” by Y Tsujimora et al (Immunity 28: 581, 2008) and “Newly discovered roles for basophils: a neglected minority gains new respect” by H. Karasuyama et al (Nature Immunology Reviews 9:9-13, 2009).
23) “Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death” by France Noizat-Pirenne et al (Transfusion 49:1785-1792, 2009) and “To RBC or not to RBC: the role of suicidal death in hemolytic transfusion reactions” by S. Spitalnik and J. Zimring (Transfusion 49: 1776-7, 2009).
24) “2,3,7,8-Tetrachlorodibenzo-p-dioxin alters the differentiation of alloreactive CD8+ T cells toward a regulatory T Cell Phenotype by a mechanism that is dependent on aryl hydrocarbon receptor in CD4+ T cells” by Nancy Kerkvliet and colleagues (J. Immunotoxicol. 5:1, 81-91, 2008) and “From vanilla to 28 flavors: Multiple varieties of regulatory T cells” by Ethan Shevack (Immunity 25: 195-201, 2006).
25) “Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn’s disease” by Anthony Segal and colleagues (J. Exp. Med. 206: 1883-1897, 2009) and “Revisiting Crohn’s disease as a primary immunodeficiency of macrophages” by Jean-Laurent Casanova and Laurent Abel (J. Exp. Med. 206: 1839-1843, 2009).
26) “Thymosin -1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance” by Pulo Pucetti and colleagues (Blood 108, 2265-2274, 2006) and “Ido expression by dendritic cells: Tolerance and tryptophan catabolism” (Nature Immunol. Rev 4, 762-774, 2004).
27) “Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A.” by Stuart Orkin and colleagues (Science 322: 1839-1842, 2008) and “Fetal Globin Induction – Can It Cure β Thalassemia?” by Susan Perrine, ASH Hematology pp. 38-44, 2005.
28) Work seminar by Shannon Carroll (Ravid lab) entitled: “The role of the macrophage A2b adenosine receptor on bone fracture healing and mesenchymal stem cell differentiation.“ Background article: “Adenosine: An endogenous regulator of innate immunity” by Gyorgy Hasko and Bruce N. Cronstein, Trends in Immunology, Vol 25, pp. 33-39, 2004.
29) Work seminar by Serguei Castaneda (Faller lab) entitled: “Novel therapeutic candidates, identified by molecular modeling, induce gamma-globin gene expression in vivo.” Background article: “Pathophysiologically-based drug treatment of sickle cell disease” by Martin H. Steinberg. Trends in Pharm. Sciences Vol 27, pp. 204-210, 2006.
30) Work seminar by Bryan Belikoff (Remick lab) entitled “Adenosine A2B receptor blockade enhances bacterial killing and improves polymicrobial sepsis survival”. Background articles: “Adenosine A2A receptor inactivation increase survival in polymicrobial sepsis” by Z Nemeth et al, J. Immunol. 176: 5616, 2006 and “Animal models of sepsis: Setting the stage” by Jon Buras, Bernhard Holzmann and Michail Sitkovsky. Nature Reviews Drug Discovery 4:854, 2005.
31) Work seminar by Ryan Thompson (Gilmore lab) entitled “The role of NFB signaling in the pathogenesis of diffuse large B cell lymphoma.” Background article: “Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile” by Chin M et al, Oncogene 28: 2100-2111, 2009.
32) Work seminar by Daniel Dworkis (Steinberg lab) entitled “The Role of Genetic Variation in ARFGEF2 in Altering TNF Signaling and Modulating the Severity of Sickle Cell Disease.” Background article: “The Brefeldin A-inhibited Guanine Nucleotide-exchange Protein, BIG2, Regulates the Constitutive Release of TNFR1 Exosome-like Vesicles” by A. Islam et al, J. Biol. Chem. 282: 9591-9599, 2007.